Subscription Required

Only paid subscribers* to Drug Benefit News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Drug Benefit News receive

  • 24 biweekly issues of timely news and insightful strategies for reducing costs and improving outcomes, delivered by First Class U.S. Mail and electronically,
  • E-News Alerts whenever important news breaks, and
  • Access to a subscriber-only Web page with:
    • Searchable archives of past articles,
    • Convenient library with PDFs of back issues,
    • Recent stories of interest and hot topic articles grouped for convenient reading, and
    • Regular postings from your editor.
View a sample and get more information
June 24, 2016

Recent Stories

From Drug Benefit News - If Congress moves forward with recommendations from the latest Medicare Payment Advisory Commission (MedPAC) report, submitted June 15, not only plans but also many of the more than 42 million Medicare Part D beneficiaries could see their costs increase. And while the agency has made plenty of proposals that Congress has yet to implement, the most recent recommendations, according to one industry expert, actually may have more momentum than past ones. Read more

Providers are targeting specialty pharmacy as a way to break into the… Read more

Analysts are marking the differences in PBM models as the 2017 selling… Read more

As the opioid epidemic continues to plague the country, providers now have… Read more

From the Editor

Welcome to your Drug Benefit News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with comments on the last issue of Drug Benefit News, story ideas for future issues or any other suggestions you have that can make the newsletter more useful for you.

June 28, 2016
FDA OKs Another Gilead Hep C Therapy

The FDA approved the new Gilead drug Epclusa, the first product indicated to treat all six main genotypes of hepatitis C. Cost for 12 weeks reportedly is $74,000

June 17, 2016
Avalere: Majority of Insurers Interested in Pay-for-Performance Prescription Deals

An analysis from Avalere Health finds 63% of insurers are either highly or very highly interested in value-based prescription drug deals.

June 13, 2016
OptumRx Wins $300M GE Drug Benefits Contract Away From CVS

GE selected OptumRx for its estimated $300 million drug benefits contract in yet another win over incumbent PBM CVS/caremark.

Updated Regularly

Featured Hot Topics

Search for your own Hot Topics

It's quick and easy to sign up for FREE access to!

Why do I need to register?